Targets › CHM
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout May 2027.
Substrate-binding subunit of the Rab geranylgeranyltransferase (GGTase) complex. Binds unprenylated Rab proteins and presents the substrate peptide to the catalytic component B composed of RABGGTA and RABGGTB, and remains bound to it after the geranylgeranyl transfer reaction. (UniProt, P24386)
Open in Phaseline: the race on CHM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics | 4D-110 AAV gene therapy delivering codon-optimized human CHM gene via AAV5 capsid variant (4D-R10 | CHM | Phase 1 | Choroideremia | May 2027 |
Choroideremia (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.